88
Participants
Start Date
September 10, 2024
Primary Completion Date
September 30, 2027
Study Completion Date
September 30, 2027
Fianlimab
Fianlimab IV given every three weeks
Cemiplimab
Cemiplimab IV given every three weeks
Ipilimumab
Ipilimumab will be give every 6 weeks continuously
RECRUITING
Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
RECRUITING
Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison
RECRUITING
Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale
RECRUITING
Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack
NOT_YET_RECRUITING
MD Anderson Cancer Center (Data Collection Only), Houston
RECRUITING
Cedars-Sinai Medical Center, Los Angeles
NOT_YET_RECRUITING
Stanford University (Data Collection Only), Stanford
RECRUITING
Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge
NOT_YET_RECRUITING
Hackensack Meridian Health, Hackensack
RECRUITING
Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
RECRUITING
Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Regeneron Pharmaceuticals
INDUSTRY
Memorial Sloan Kettering Cancer Center
OTHER